System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 40286464 DOI: 10.1016/j.annder.2025.103376

Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts.

Ann Dermatol Venereol 152(2):103376

Authors: E Mahé, V di Lernia, A-C Bursztejn, S Hadj-Rabia, N Quiles-Tsimaratos, A Belloni Fortina, I Neri, A Lasek, A Maruani, G Chaby, J Gottlieb, S Barbarot, H Aubert, C Droitcourt, S Mallet, A Phan, M Severino-Freire, F Boralévi, H Barthélémy, C Girard, L Martin, J Mazerreuw-Hautier, A Beauchet

Affiliations

  • Dermatology Department, Hôpital Victor Dupouy, 69 Rue du Lieutenant-Colonel Prud'hon, 95107 Argenteuil, France.
  • Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Viale Risorgimento, 80 Reggio Emilia, Italy.
  • Dermatology Department, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
  • Dermatology Department, INSERM U1163 & Institut Imagine, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne, Paris Cité, 149 Rue de Sèvres, 75015 Paris, France.
  • Dermatology Department, Hôpital Saint-Joseph, 26 Bd de Louvain, 13008 Marseille, France.
  • Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padua, Italy.
  • Dermatology Unit, RCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy.
  • Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Bd de Belfort, 59000 Lille, France.
  • Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE - CHRU Tours, 2 Bd Tonnellé, 37000 Tours, France.
  • Dermatology Department, Hôpital Sud, 30 Av. de la Croix Jourdain, 80000 Amiens, France.
  • Immunology and Dermatology Department, Hôpital Bicêtre, Centre Hospitalier Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, Universitaire Paris-Saclay, 78 Rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France.
  • Dermatology department, Centre Hospitalier Universitaire de Nantes, 5 Allée de l'Île Gloriette, 44000 Nantes, France.
  • Dermatology Department, Centre Hospitalier Universitaire Pontchaillou, 2 Rue Henri le Guilloux, 35000 Rennes, France.
  • Dermatology Department, Hôpital de la Timone, Assistance-Publique-Hôpitaux de Marseille, 264 Rue Saint-Pierre, 13005 Marseille, France.
  • Paediatric department, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France.
  • Dermatology department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, 24 Chemin de Pouvourville, 31400 Toulouse, France.
  • Department of Paediatric Dermatology, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33000 Bordeaux, France.
  • Dermatology Department, Centre Hospitalier d'Auxerre, 2 Boulevard de Verdun, 89000 Auxerre, France.
  • Dermatology Department, Centre Hospitalier Universitaire de Montpellier, 191 Avenue du Doyen Gaston Giraud, 34295 Montpellier, France.
  • Dermatology Department, Centre Hospitalier Universitaire d'Angers, 4 Rue Larrey, 49100 Angers, France.
  • Department of Public Health, Hôpital Raymond Poincaré, 104 Bd Raymond Poincaré, 92380 Garches, France.

Abstract

BACKGROUND

Being overweight or obese is associated with both the occurrence of childhood psoriasis and increased severity thereof. We evaluated the impact of being overweight or obese on the clinical features of severe psoriasis in children treated with etanercept, adalimumab, or ustekinumab, and on the therapeutic effectiveness of these treatments using data from the BiPe cohorts.

PATIENTS AND METHODS

Children from the BiPe cohorts with available baseline body mass index data were included. Data from two groups, "normal weight" and "overweight-to-obese" (OTO), and from two OTO subgroups, overweight and obese, were analyzed.

RESULTS

Of the 134 children included, 98 (73.1%) were of normal weight, and 36 (26.9%) were OTO, including 21 (15.7%) overweight and 15 (11.2%) obese children. There were no between-group differences in age at psoriasis onset, family history, clinical features, or severity. Compared to the normal weight group, psoriatic arthritis was more frequent in the OTO group (5.1% versus 16.7% respectively; P = 0.03) and in the overweight and obese subgroups (5.1% versus 14.3% and 20.0%, respectively; P = 0.08). Analysis of PASI scores after 3 months of treatment suggested that biologic therapy efficacy was higher for the OTO group than the normal weight group. Drug continuation rates tended to be lower for the OTO group, particularly for adalimumab (P = 0.0002).

DISCUSSION

OTO status was associated with a higher frequency of psoriatic arthritis in children with psoriasis. Except for lower rates of adalimumab continuation, overall biologic therapy efficacy was similar in the normal and OTO groups. Studies involving larger cohorts are needed to confirm these findings.

MeSH

Sexually Transmitted Diseases, Arthritis, Psoriatic, Arthritis, Adalimumab, Therapeutics, Overweight, Biological Therapy, Psoriasis, Dermatology, Child